Growth Metrics

Moderna (MRNA) Change in Account Payables (2018 - 2026)

Moderna (MRNA) has disclosed Change in Account Payables for 9 consecutive years, with -$120.0 million as the latest value for Q1 2026.

  • For Q1 2026, Change in Account Payables rose 23.08% year-over-year to -$120.0 million; the TTM value through Mar 2026 reached -$56.0 million, down 171.79%, while the annual FY2025 figure was -$92.0 million, 33.33% down from the prior year.
  • Change in Account Payables hit -$120.0 million in Q1 2026 for Moderna, down from $22.0 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $179.0 million in Q3 2023 and bottomed at -$303.0 million in Q1 2024.
  • Average Change in Account Payables over 5 years is -$1.6 million, with a median of $21.0 million recorded in 2023.
  • Year-over-year, Change in Account Payables surged 905.56% in 2022 and then tumbled 234.29% in 2023.
  • Moderna's Change in Account Payables stood at $151.0 million in 2022, then plummeted by 86.09% to $21.0 million in 2023, then soared by 61.9% to $34.0 million in 2024, then crashed by 35.29% to $22.0 million in 2025, then plummeted by 645.45% to -$120.0 million in 2026.
  • According to Business Quant data, Change in Account Payables over the past three periods came in at -$120.0 million, $22.0 million, and $89.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.